Stat5: From breast development to cancer prognosis, prediction, and progression

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2443-2444

  Tweardy, David ^a   Chang, Jenny C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; STAT5 PROTEIN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELLULAR DISTRIBUTION; CHROMOSOME 17Q; EDITORIAL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANIMALS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEINS;

EID: 79959285404     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.2014     Document Type: Editorial

References (11)

1. Yamashita H, Nishio M, Ando Y, et al: Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 13:885-893, 2006 (Pubitemid 44763264)
2. Aaronson DS, Horvath CM: A road map for those who don't know JAK-STAT. Science 296:1653-1655, 2002 (Pubitemid 34579157)
3. Liu X, Robinson GW, Wagner KU, et al: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11:179-186, 1997 (Pubitemid 27081895)
4. Chapman RS, Lourenco P, Tonner E, et al: The role of Stat3 in apoptosis and mammary gland involution: Conditional deletion of Stat3. Adv Exp Med Biol 480:129-138, 2000 (Pubitemid 32176103)
5. Udy GB, Towers RP, Snell RG, et al: Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 94:7239-7244, 1997 (Pubitemid 27345299)
6. Watson CJ, Miller WR: Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71:840-844, 1995
7. Dolled-Filhart M, Camp RL, Kowalski DP, et al: Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9:594-600, 2003 (Pubitemid 36182589)
8. Nevalainen MT, Xie J, Torhorst J, et al: Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053-2060, 2004 (Pubitemid 41095137)
9. Peck AR, Witkiewicz AK, Liu C, et al: Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 29:2448-2458, 2011
10. De Laurentiis M, Arpino G, Massarelli E, et al: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748, 2005 (Pubitemid 41557193)
11. Walker SR, Nelson EA, Zou L, et al: Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 7:966-976, 2009